Navigation Links
AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain

. Further information about AVANIR can be found at www.avanir.com.

Forward-Looking Statement

Statements in this press release that are not historical facts, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," or similar statements, are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements. There can be no assurance that the Company will receive FDA regulatory approval for Zenvia or that the additional development work for Zenvia will be completed in the time periods that are anticipated. Final review decisions made by the FDA and other regulatory agencies concerning are often unpredictable and outside the influence and control of the Company. Risks and uncertainties also include the risks set forth in AVANIR's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time-to-time in other publicly available information regarding the Company. Copies of this information are available from AVANIR upon request. AVANIR disclaims any intent to update these forward-looking statements.

To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0

Contact

Lippert/Heilshorn & Associates, Inc. for
AVANIR Pharmaceuticals
Jody Cain or Bruce Voss, 310-691-7100
jcain@lhai.com
bvoss@lhai.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/25/2014)... Tobago , July 25, 2014  The ... & Tobago Ministry of Health approved the introduction ... significantly increases the cure rate from Hepatitis C, ... the genotype 1 virus. Telaprevir is available in ... brand INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg ...
(Date:7/25/2014)... According to a new market ... Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and ... and Forecast (Value and Volume), 2013 - 2019", the ... in 2012 and is expected to grow at a ... USD 32.24 billion in 2019. Browse the ...
(Date:7/25/2014)... 2014  AMETEK, Inc. (NYSE: AME ) ... as Vice President and General Manager, Engineered Medical ... Division. "I am pleased that Kurt has ... development experience, especially in the medical device industry, and ... continued growth and success of our medical components businesses," ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... 26, 2012 /PRNewswire-iReach/ -- ShelfX, provider ... the availability of the Vending Fridge. As the ... use a simple QR code scanner from their ... seamlessly purchase refrigerated products. The Vending Fridge can ...
... 26, 2012 Upsher-Smith Laboratories, Inc. ( http://www.upsher-smith.com ... pharmacokinetic (PK) profile of USL255, its once-daily, extended-release ... Annual American Academy of Neurology (AAN) Meeting.  One ... and equal doses of immediate-release (IR) topiramate at ...
Cached Medicine Technology:ShelfX Releases A Fridge That Knows What You Took 2Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 2Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 3Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 4Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 5
(Date:7/28/2014)... (PRWEB) July 28, 2014 As health ... are looking to private exchanges. “Private Exchange Strategies ... 6 webinar from Atlantic Information Services, will provide answers ... exchange strategies for the future. , Barbara Gniewek, Jonathan ... with extensive experience in the private exchange sector — ...
(Date:7/28/2014)... According to the Heartburn No More PDF review recently ... help people get rid of acid reflux naturally. ... heartburn and acid reflux. In addition, inside this book, people ... factors for reflux disease. , Vkool informs in its ... symptoms of reflux disease naturally without medications. The book also ...
(Date:7/28/2014)... 28, 2014 Building a sense of ... important. Where personal outdoor space is not possible, ... enjoy fun and exercise outside is important. That’s ... in quality commercial playground equipment from APCPLAY. , Old ... Midlothian, Virginia. It is an historic tourist location of ...
(Date:7/28/2014)... Calif., July 27, 2014 - (PRWEB) July 28, 2014 ... in 12 months by earning the Masters Champion title at ... proving that age is no obstacle for this athlete. She ... at the event hosted by the International Pole Sports Federation ... 63, traveling from 30 countries, took part in the competition. ...
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the ... Feelings.” The new book, DOC X MD Funny Feelings ... story telling style with humor and medical accuracy. The book ... will find answers to those age-old questions that most folks ... pee? Why do mosquitoes bite some and not others? Why ...
Breaking Medicine News(10 mins):Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2
... Texas Pesticides and pollutants are related to an alarming ... anencephaly in rural China, according to scientists at The University ... of the pesticides found in high concentrations in the placentas ... Endosulfan is only now being phased out in the United ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Oct. ... friends tend to have areas of the brain that ... with fewer friends, British researchers say. "We were ... in them is reflected in brain structure and function," ...
... cardiac arrest is the leading cause of death in the ... initial collapse. In addition, fewer than half of the small ... the hospital, because they often suffer irreversible brain damage. A ... Neurology provides guidance to physicians using therapeutic cooling to ...
... flushes and night sweats years after the menopause finds a new ... and Gynaecology . Hot flushes and night sweats (HF/NS) are ... severity and duration vary considerably. The average age of ... it is generally assumed that HF/NS last between 2 to 5 ...
... Spanish . Researchers from Massachusetts General ... cell mechanism activated by a protein HOXB9 that becomes an ... world continue to focus their research on breast cancer. As ... growing, as well as of their interactions with the microenvironment. ...
... Duke University Medical Center researchers have verified data that ... a patient who has been under anesthesia for an operation. ... first year after surgery if a patient has low values ... patients whose values are all normal. The three ...
Cached Medicine News:Health News:Study links pollutants to a 450 percent increase in risk of birth defects 2Health News:Study links pollutants to a 450 percent increase in risk of birth defects 3Health News:More Facebook Friends, More Gray Matter in Brain? 2Health News:More Facebook Friends, More Gray Matter in Brain? 3Health News:Mayo Clinic study guides physicians using therapeutic cooling to treat cardiac arrest patients 2Health News:Older women still suffer from hot flushes and night sweats years after the menopause finds study 2Health News:Discovery of a cell mechanism that reduces effectiveness of breast cancer treatment 2Health News:3 factors could point to your fate after surgery 2
... The proper gel is essential ... when working with pH catheters ... specific chloride ion concentration in ... required for proper function of ...
The WaveMax is one of the most flexible stainless steel stents due to its unique wave design and has the lowest effective profile, accommodating a 6F sheath up to 7 mm....
... its specifically designed reagents, allows to ... sample, multiple analytes. This unique technology ... laboratories willing to simplify and standardize ... as well as to reduce as ...
... a variety of applications across a broad ... is suitable for any laboratory demanding high ... mixed-mode throughput exceeding 95 PT/aPTT/Fibrinogen per hour ... range of chromogenics, the AMAX DestinyPlus is ...
Medicine Products: